Table 3.
Kaplan-Meier Cumulative Probabilities by Aspirin Status, Their Differences, and Year of Follow-up
| Cumulative Probability (95% CI)
|
|||
|---|---|---|---|
| Aspirin | No Aspirin | Difference (95% CI) | |
| Primary CVD | |||
| Year 1 | 3.6% (2.6% to 4.9%) | 2.6% (1.6% to 3.7%) | 1.0% (−0.5% to 2.5%) |
| Year 2 | 5.9% (4.4% to 7.6%) | 5.1% (3.7% to 6.5%) | 0.8% (−1.1% to 2.8%) |
| Year 3 | 8.7% (6.9% to 10.7%) | 8.0% (6.2% to 9.9%) | 0.6% (−1.8% to 3.4%) |
| Year 4 | 11.9% (9.8% to 14.3%) | 10.9% (8.7% to 13.2%) | 1.0% (−1.9% to 4.2%) |
| Year 5 | 15.5% (12.8% to 18.5%) | 13.1% (10.5% to 15.9%) | 2.3% (−1.3% to 6.2%) |
| Year 6 | 18.1% (14.6% to 22.0%) | 14.7% (11.7% to 17.8%) | 3.4% (−1.3% to 8.0%) |
| Year 7 | 20.9% (15.8% to 27.3%) | 17.4% (12.2% to 23.8%) | 3.5% (−5.5% to 12.5%) |
| All-cause mortality | |||
| Year 1 | 1.3% (0.7% to 2.2%) | 1.9% (1.0% to 2.8%) | −0.5% (−1.7% to 0.6%) |
| Year 2 | 3.3% (2.3% to 4.4%) | 4.0% (2.8% to 5.2%) | − 0.6% (−2.3% to 1.0%) |
| Year 3 | 6.2% (4.8% to 7.9%) | 6.3% (4.8% to 7.8%) | 0.0% (−2.2% to 2.1%) |
| Year 4 | 7.9% (6.1% to 9.7%) | 10.1% (8.0% to 12.2%) | −2.2% (−4.9% to 0.4%) |
| Year 5 | 11.1% (8.7% to 13.5%) | 12.7% (10.3% to 15.5%) | −1.6% (−5.4% to 1.8%) |
| Year 6 | 15.5% (12.2% to 19.2%) | 15.8% (12.5% to 19.2%) | −0.3% (−5.0% to 4.9%) |
| Year 7 | 17.7% (13.5% to 22.6%) | 22.9% (16.2% to 31.1%) | −5.2% (−15.4% to 4.1%) |
| Kidney failure | |||
| Year 1 | 0.8% (0.3% to 1.5%) | 0.6% (0.2% to 1.2%) | 0.2% (−0.5% to 0.9%) |
| Year 2 | 1.7% (1.0% to 2.6%) | 2.4% (1.4% to 3.4%) | −0.7% (−2.0% to 0.7%) |
| Year 3 | 3.9% (2.6% to 5.2%) | 4.2% (2.9% to 5.6%) | −0.3% (−2.3% to 1.5%) |
| Year 4 | 5.2% (3.6% to 6.7%) | 6.2% (4.5% to 8.1%) | −1.0% (−3.6% to 1.3%) |
| Year 5 | 7.6% (5.5% to 9.9%) | 8.5% (6.3% to 10.8%) | −0.9% (−3.9% to 2.0%) |
| Year 6 | 11.5% (8.2% to 14.6%) | 10.7% (7.6% to 14.1%) | 0.8% (−3.8% to 5.3%) |
| Year 7 | 13.2% (9.4% to 17.0%) | 10.7% (7.6% to 14.1%) | 2.6% (−2.6% to 7.6%) |
| Kidney failure/all-cause | mortality | ||
| Year 1 | 2.2% (1.3% to 3.2%) | 2.9% (1.9% to 4.0%) | −0.7% (−2.2% to 0.7%) |
| Year 2 | 4.9% (3.6% to 6.3%) | 6.1% (4.6% to 7.8%) | −1.2% (−3.4% to 0.7%) |
| Year 3 | 9.4% (7.6% to 11.3%) | 10.0% (8.0% to 11.8%) | −0.6% (−3.3% to 2.0%) |
| Year 4 | 12.0% (9.8% to 14.2%) | 15.2% (12.7% to 17.8%) | −3.2% (−6.8% to 0.0%) |
| Year 5 | 16.9% (14.1% to 19.6%) | 18.9% (16.2% to 21.8%) | −2.0% (−6.4% to 2.0%) |
| Year 6 | 24.9% (20.4% to 29.1%) | 22.4% (18.8% to 26.2%) | 2.4% (−3.7% to 8.2%) |
| Year 7 | 27.1% (21.8% to 32.4%) | 24.7% (20.3% to 29.7%) | 2.4% (−4.9% to 9.9%) |
| Primary CVD/all-cause | mortality | ||
| Year 1 | 4.5% (3.4% to 5.9%) | 3.6% (2.5% to 4.8%) | 0.9% (−0.7% to 2.6%) |
| Year 2 | 7.9% (6.2% to 9.7%) | 7.2% (5.6% to 8.8%) | 0.7% (−1.6% to 3.0%) |
| Year 3 | 12.2% (10.2% to 14.3%) | 11.2% (9.2% to 13.2%) | 1.0% (−1.8% to 3.9%) |
| Year 4 | 16.0% (13.5% to 18.5%) | 15.8% (13.3% to 18.3%) | 0.2% (−3.1% to 3.5%) |
| Year 5 | 20.0% (17.2% to 23.1%) | 19.6% (16.6% to 22.7%) | 0.4% (−3.7% to 4.5%) |
| Year 6 | 23.5% (19.9% to 27.2%) | 22.1% (18.6% to 25.5%) | 1.4% (−3.7% to 6.7%) |
| Year 7 | 26.6% (21.3% to 33.3%) | 25.4% (19.6% to 31.8%) | 1.3% (−8.0% to 10.9%) |
Note: Analyses are based on the 1:1 propensity cohort with a 0.1 standard deviation caliper. The 95% CIs of the cumulative probabilities and the differences between aspirin users and non–aspirin users were derived using 500 bootstrap resampling.
Abbreviations: CI, confidence interval; CVD, cardiovascular disease.